skip to Main Content

Lars B. Rasmussen

Chief Operating Officer (COO)

Chief Operating Officer (COO)

Lars Bukhave Rasmussen (Danish, born 1975) has been COO for PILA PHARMA since May 2021, due to his vast experience in building and running effective organisations and operations. Previously, he served as Chief Financial Officer (CFO) for PILA PHARMA (September 2020 – May 2021).

Lars B. Rasmussen graduated as Doctor of Veterinary Medicine (DVM) from the University of Copenhagen, DK in 2005, attained a Graduate Diploma in Business Administration, Financial Management & Accounting at the University of Southern Denmark, DK in 2008, and in 2015 completed an Executive MBA at Henley Business School, UK.

From 2006 until August 2020, Lars B. Rasmussen served at LEO Pharma A/S, a global mid-size biopharma company headquartered in Denmark where he has held several positions, both in Denmark and in the US.

The resulting professional experiences include business development incl. valuation and partnering agreements (Business Development Manager 2009-2010), global business unit management (Senior Director, Head of Global Business Area Thrombosis 2013-2015), pharmaceutical program & project management (Vice President, Head of Project Management 2015), financial planning, systems and processes (Vice President, Head of Global Enterprise Resource Planning Program 2015-2016), R&D organizational design (Vice President, Global R&D Transformation Project Lead 2018), as well as strategic, operational, financial and compliance risk management (Vice President, Global Chief Risk & Compliance Officer 2018-2020).

He also holds extensive experience from the US pharmaceutical market in relation to both the establishment and scale up of a pharmaceutical company (Strategy & Planning Senior Manager 2011-2012), as well as deep insights of how to create partnerships and commercialize innovations in the very complex US marketplace (Vice President, Head of LEO US Marketing 2016-2018).

Lars B. Rasmussen thus provides significant additional experience to PILA PHARMA within the full pharma value chain ranging from organizational design, innovation processes and financial management, as well as general management.

In addition, Lars also supports Pila Pharma with a deep understanding of the TRPV1 target since his DVM master thesis, supervised by Dorte X. Gram, focused on the role of the receptor in preclinical diabetes.

As the company’s first Chief Operating Officer he will therefore be instrumental in maximizing the value of Pila Pharma’s core assets both from a scientific, market and operational perspective.

Back To Top